This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lukaszewski, R. A.
Right arrow Articles by Brooks, T. J. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lukaszewski, R. A.
Right arrow Articles by Brooks, T. J. G.

 Previous Article  |  Next Article 

Journal of Virology, June 2000, p. 5006-5015, Vol. 74, No. 11
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Pegylated Alpha Interferon Is an Effective Treatment for Virulent Venezuelan Equine Encephalitis Virus and Has Profound Effects on the Host Immune Response to Infection

Roman A. Lukaszewski* and Timothy J. G. Brooks

CBD, Porton Down, Salisbury, Wiltshire SP4 0JQ, United Kingdom

Received 26 October 1999/Accepted 6 March 2000

Venezuelan equine encephalitis virus (VEEV) is a highly infectious alphavirus endemic in parts of Central and South America. The disease is transmitted by mosquitoes, and the natural reservoir is the small rodent population, with epidemics occurring in horses and occasionally humans. Following infection, VEEV replicates in lymphoid tissues prior to invasion of the central nervous system. Treatment of VEEV-infected BALB/c mice with polyethylene glycol-conjugated alpha interferon (PEG IFN-alpha ) results in a greatly enhanced survival from either a subcutaneous or an aerosol infection. Virus is undetectable within PEG IFN-alpha -treated individuals by day 30 postinfection (p.i.). Treatment results in a number of changes to the immune response characteristics normally associated with VEEV infection. Increased macrophage activation occurs in PEG IFN-alpha -treated BALB/c mice infected with VEEV. The rapid activation of splenic CD4, CD8, and B cells by day 2 p.i. normally associated with VEEV infection is absent in PEG IFN-alpha -treated mice. The high tumor necrosis factor alpha production by macrophages from untreated mice is greatly diminished in PEG IFN-alpha -treated mice. These results suggest key immunological mechanisms targeted by this lethal alphavirus that can be modulated by prolonged exposure to IFN-alpha .

* Corresponding author. Mailing address: CBD, Porton Down, Salisbury, Wiltshire SP4 0JQ, United Kingdom. Phone: 44 1980 613 221. Fax: 44 1980 613 284. E-mail: rlukaszewski{at}hotmail.com.

Journal of Virology, June 2000, p. 5006-5015, Vol. 74, No. 11
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Konopka, J. L., Thompson, J. M., Whitmore, A. C., Webb, D. L., Johnston, R. E. (2009). Acute Infection with Venezuelan Equine Encephalitis Virus Replicon Particles Catalyzes a Systemic Antiviral State and Protects from Lethal Virus Challenge. J. Virol. 83: 12432-12442 [Abstract] [Full Text]  
  • Simmons, J. D., White, L. J., Morrison, T. E., Montgomery, S. A., Whitmore, A. C., Johnston, R. E., Heise, M. T. (2009). Venezuelan Equine Encephalitis Virus Disrupts STAT1 Signaling by Distinct Mechanisms Independent of Host Shutoff. J. Virol. 83: 10571-10581 [Abstract] [Full Text]  
  • O'Brien, L., Perkins, S., Williams, A., Eastaugh, L., Phelps, A., Wu, J., Phillpotts, R. (2009). Alpha interferon as an adenovirus-vectored vaccine adjuvant and antiviral in Venezuelan equine encephalitis virus infection. J. Gen. Virol. 90: 874-882 [Abstract] [Full Text]  
  • Aguilar, P. V., Paessler, S., Carrara, A.-S., Baron, S., Poast, J., Wang, E., Moncayo, A. C., Anishchenko, M., Watts, D., Tesh, R. B., Weaver, S. C. (2005). Variation in Interferon Sensitivity and Induction among Strains of Eastern Equine Encephalitis Virus. J. Virol. 79: 11300-11310 [Abstract] [Full Text]  
  • Grubman, M. J., Baxt, B. (2004). Foot-and-Mouth Disease. Clin. Microbiol. Rev. 17: 465-493 [Abstract] [Full Text]  
  • Leyssen, P., Drosten, C., Paning, M., Charlier, N., Paeshuyse, J., De Clercq, E., Neyts, J. (2003). Interferons, Interferon Inducers, and Interferon-Ribavirin in Treatment of Flavivirus-Induced Encephalitis in Mice. Antimicrob. Agents Chemother. 47: 777-782 [Abstract] [Full Text]  
  • Chinsangaram, J., Moraes, M. P., Koster, M., Grubman, M. J. (2002). Novel Viral Disease Control Strategy: Adenovirus Expressing Alpha Interferon Rapidly Protects Swine from Foot-and-Mouth Disease. J. Virol. 77: 1621-1625 [Abstract] [Full Text]  
  • Brassard, D. L., Grace, M. J., Bordens, R. W. (2002). Interferon-{alpha} as an immunotherapeutic protein. J. Leukoc. Biol. 71: 565-581 [Abstract] [Full Text]  
  • Samuel, C. E. (2001). Antiviral Actions of Interferons. Clin. Microbiol. Rev. 14: 778-809 [Abstract] [Full Text]  
  • Suginoshita, Y., Tabata, Y., Moriyasu, F., Ikada, Y., Chiba, T. (2001). Liver Targeting of Interferon-beta with a Liver-Affinity Polysaccharide Based on Metal Coordination in Mice. J. Pharmacol. Exp. Ther. 298: 805-811 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»